Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group. Michl M, et al. Among authors: mueller s. Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234640 Free article. Clinical Trial.
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
PETACC-8 study investigators; Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Be… See abstract for full author list ➔ PETACC-8 study investigators, et al. Among authors: mueller s, mueller l. Ann Oncol. 2015 Apr;26(4):822-825. doi: 10.1093/annonc/mdv070. Ann Oncol. 2015. PMID: 25814651 Free article. No abstract available.
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
Vogelhuber M, Feyerabend S, Stenzl A, Suedhoff T, Schulze M, Huebner J, Oberneder R, Wieland W, Mueller S, Eichhorn F, Heinzer H, Schmidt K, Baier M, Ruebel A, Birkholz K, Bakhshandeh-Bath A, Andreesen R, Herr W, Reichle A. Vogelhuber M, et al. Among authors: mueller s. Cancer Microenviron. 2015 Apr;8(1):33-41. doi: 10.1007/s12307-014-0161-7. Epub 2014 Dec 11. Cancer Microenviron. 2015. PMID: 25503648 Free PMC article.
Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.
Vogelhuber M, Feyerabend S, Stenzl A, Suedhoff T, Schulze M, Huebner J, Oberneder R, Wieland W, Mueller S, Eichhorn F, Heinzer H, Schmidt K, Baier M, Ruebel A, Birkholz K, Bakhshandeh-Bath A, Andreesen R, Herr W, Reichle A. Vogelhuber M, et al. Among authors: mueller s. Cancer Microenviron. 2015 Apr;8(1):43-4. doi: 10.1007/s12307-015-0165-y. Cancer Microenviron. 2015. PMID: 25651886 Free PMC article. No abstract available.
Improved tracking of corneal immune cell dynamics using in vivo confocal microscopy.
Bedggood P, Wu M, Zhang X, Rajan R, Wu CY, Karunaratne S, Metha AB, Mueller SN, Chinnery HR, Downie LE. Bedggood P, et al. Among authors: mueller sn. Biomed Opt Express. 2024 Oct 10;15(11):6277-6298. doi: 10.1364/BOE.536553. eCollection 2024 Nov 1. Biomed Opt Express. 2024. PMID: 39553868 Free PMC article.
Haplotype-resolved genome and population genomics of the threatened garden dormouse in Europe.
Byerly PA, von Thaden A, Leushkin E, Hilgers L, Liu S, Winter S, Schell T, Gerheim C, Ben Hamadou A, Greve C, Betz C, Bolz HJ, Büchner S, Lang J, Meinig H, Famira-Parcsetich EM, Stubbe SP, Mouton A, Bertolino S, Verbeylen G, Briner T, Freixas L, Vinciguerra L, Mueller SA, Nowak C, Hiller M. Byerly PA, et al. Among authors: mueller sa. Genome Res. 2024 Nov 20;34(11):2094-2107. doi: 10.1101/gr.279066.124. Genome Res. 2024. PMID: 39542649
Retrospective Comparison of Targeted Anticancer Drugs Predicted by the CNS-TAP Tool Versus Those Selected by a Molecularly Driven Tumor Board in Children With DIPG.
Roberts HJ, Ravi K, Marini BL, Schepers A, Kline C, Kilburn L, Prados M, Byron SA, Sturza J, Mueller S, Koschmann C, Franson AT. Roberts HJ, et al. Among authors: mueller s. J Pediatr Hematol Oncol. 2024 Nov 6. doi: 10.1097/MPH.0000000000002964. Online ahead of print. J Pediatr Hematol Oncol. 2024. PMID: 39527919
The Journal of Hospital Medicine turns 20.
Shah SS; Journal of Hospital Medicine Editorial Leadership Team. Shah SS, et al. J Hosp Med. 2024 Nov 11. doi: 10.1002/jhm.13548. Online ahead of print. J Hosp Med. 2024. PMID: 39523916 No abstract available.
2,337 results